热景生物
(688068)
| 流通市值：26.24亿 | | | 总市值：26.24亿 |
| 流通股本：9226.88万 | | | 总股本：9226.88万 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 194,108,872.57 | 325,875,632.84 | 319,262,764.49 | 523,493,118.9 |
| 应收票据及应收账款 | 103,473,402.25 | 113,750,343.91 | 102,912,830.96 | 95,802,052.5 |
| 其中：应收票据 | - | - | - | 800 |
| 应收账款 | 103,473,402.25 | 113,750,343.91 | 102,912,830.96 | 95,801,252.5 |
| 应收款项融资 | 306,114 | 400,000 | 560,441.48 | 6,242,036.17 |
| 预付款项 | 50,798,447.6 | 59,215,883.82 | 46,614,773.45 | 30,527,007.36 |
| 其他应收款合计 | 17,862,604.34 | 16,807,783.52 | 20,928,927.65 | 17,011,583.41 |
| 存货 | 135,494,539.78 | 132,105,804.1 | 148,634,782.57 | 154,249,346.98 |
| 一年内到期的非流动资产 | 130,000,000 | 210,000,000 | 210,000,000 | 50,000,000 |
| 其他流动资产 | 24,892,000.28 | 28,986,697.79 | 57,073,034.45 | 32,258,958.86 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 931,272,157.32 | 1,195,302,584.61 | 1,354,547,109.62 | 1,798,268,654.72 |
| 非流动资产: | | | | |
| 长期股权投资 | 357,435,396 | 257,323,398.71 | 197,331,406.54 | 169,573,103.26 |
| 其他权益工具投资 | 126,500,000 | 91,500,000 | 96,150,000 | 96,150,000 |
| 其他非流动金融资产 | 861,685,020.68 | 874,265,284.94 | 850,000,000 | 772,581,041.11 |
| 固定资产 | 751,262,349.4 | 621,866,236.38 | 550,717,440.89 | 469,648,570 |
| 在建工程 | 347,069,283.19 | 439,124,012.92 | 423,800,313.84 | 374,436,080.38 |
| 使用权资产 | 16,634,296.06 | 18,964,368.83 | 21,339,810.41 | 23,854,556.15 |
| 无形资产 | 54,249,630.04 | 54,879,469.7 | 55,759,018.82 | 56,553,336.29 |
| 长期待摊费用 | 25,710,438.77 | 20,985,844.44 | 22,428,037.57 | 23,203,107.54 |
| 递延所得税资产 | 36,149,469.18 | 34,778,285.95 | 38,798,068.99 | 38,798,068.99 |
| 其他非流动资产 | 96,295,274.52 | 92,115,593.97 | 92,939,743.96 | 76,205,321.38 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,672,991,157.84 | 2,505,802,495.84 | 2,349,263,841.02 | 2,101,003,185.1 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,604,263,315.16 | 3,701,105,080.45 | 3,703,810,950.64 | 3,899,271,839.82 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 113,045,003.04 | 146,310,968.75 | 156,534,160.8 | 263,443,202.57 |
| 应付账款 | 113,045,003.04 | 146,310,968.75 | 156,534,160.8 | 263,443,202.57 |
| 合同负债 | 24,338,503.42 | 46,460,870.94 | 40,346,974.97 | 56,978,725.95 |
| 应付职工薪酬 | 21,623,866.24 | 16,983,025.77 | 31,541,692.79 | 131,789,123.78 |
| 应交税费 | -8,816,773.85 | 4,917,462.97 | 19,931,365.4 | 15,251,948.78 |
| 其他应付款合计 | 11,629,785.14 | 11,730,447.95 | 6,319,135.78 | 14,451,796.39 |
| 一年内到期的非流动负债 | 6,677,313.43 | 12,293,503.75 | 9,850,376.22 | 27,948,883.35 |
| 其他流动负债 | 644,369.7 | 1,065,615.83 | 67,389.19 | 1,442,865.48 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 169,142,067.12 | 239,761,895.96 | 264,591,095.15 | 511,306,546.3 |
| 非流动负债: | | | | |
| 租赁负债 | 12,597,273.78 | 10,396,305.88 | 15,818,307.48 | 14,183,433.38 |
| 递延收益 | 10,774,797.86 | 10,774,797.86 | 10,774,797.86 | 10,774,797.86 |
| 递延所得税负债 | 8,124,502.93 | 9,681,331.52 | 9,324,346.23 | 9,324,346.23 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 31,496,574.57 | 30,852,435.26 | 35,917,451.57 | 34,282,577.47 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 200,638,641.69 | 270,614,331.22 | 300,508,546.72 | 545,589,123.77 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 92,268,766 | 92,268,766 | 92,050,585 | 92,050,585 |
| 资本公积 | 442,795,279.36 | 440,452,520.38 | 435,308,710.27 | 435,308,710.27 |
| 减:库存股 | 166,480,257.89 | 166,480,257.89 | 156,519,432.46 | 150,035,814.24 |
| 其他综合收益 | -130,032.17 | -379,354.52 | -17,879.63 | -26,744.4 |
| 盈余公积 | 46,025,292.5 | 46,025,292.5 | 46,025,292.5 | 46,025,292.5 |
| 未分配利润 | 2,986,503,670.65 | 3,016,891,266.24 | 2,970,785,725.69 | 2,911,901,606.2 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,400,982,718.45 | 3,428,778,232.71 | 3,387,633,001.37 | 3,335,223,635.33 |
| 少数股东权益 | 2,641,955.02 | 1,712,516.52 | 15,669,402.55 | 18,459,080.72 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,403,624,673.47 | 3,430,490,749.23 | 3,403,302,403.92 | 3,353,682,716.05 |
| 负债和股东权益合计 | 3,604,263,315.16 | 3,701,105,080.45 | 3,703,810,950.64 | 3,899,271,839.82 |
| 公告日期 | 2023-10-31 | 2023-08-30 | 2023-04-28 | 2023-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |